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Introduction
Group A Streptococcus (GAS) is an historically impor-
tant cause of puerperal infections and sepsis. Despite
preventive measures, including antibiotic use and
hospital sanitation efforts, GAS infections are re-
emerging worldwide and remain the most common
cause of severe puerperal infections.1–5 The ability of
GAS to establish infection in postpartum patients is
influenced by numerous factors, including disrupted
mucosal barriers, altered immune status of the
mother, antibiotic administration during labor and
delivery, delayed diagnosis, environmental exposures
of the mother, and specific virulence factors utilized
by GAS. The complex interactions among these
potential risk determinants complicate our under-
standing of how and why postpartum GAS sepsis
occurs. This review will discuss the complicated fac-
tors that contribute to the increased susceptibility to
postpartum GAS and highlight topics in need of fur-
ther study.
Methods
Manuscripts cited in this review were identified by
searching the available English-language literature
using PubMed (U.S. National Library of Medicine,
National Institutes of Health, Bethesda MD) for all
years available for the following terms or combina-
tion of terms: ‘GAS’, ‘Streptococcus’, ‘Streptococcus pyog-
enes’, ‘GAS virulence factors’, ‘streptococcal toxic
shock syndrome (STSS)’, ‘Bacterial susceptibility’,
‘Maternal immunology’, ‘Maternal innate immuno-
logy’, ‘Vagina ⁄Vaginal immunology’, ‘Uterine ⁄Uterus
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Group A Streptococcus (GAS) is an historically important agent of puer-
peral infections and sepsis. The inception of hand-washing and
improved hospital hygiene drastically reduced the incidence of puerperal
sepsis, but recently the incidence and severity of postpartum GAS infec-
tions has been rising for uncertain reasons. Several epidemiological,
host, and microbial factors contribute to the risk for GAS infection and
mortality in postpartum women. These include the mode of delivery
(vaginal versus cesarean section), the location where labor and delivery
occurred, exposure to GAS carriers, the altered immune status associated
with pregnancy, the genetic background of the host, the virulence of
the infecting GAS strain, and highly specialized immune responses asso-
ciated with female reproductive tract tissues and organs. This review will
discuss the complicated factors that contribute to the increased suscepti-
bility to GAS after delivery and potential reasons for the recent increase
observed in morbidity and mortality.
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immunology’, ‘Female reproductive tract (FRT)
immunology’, ‘Pregnant ⁄Pregnancy immunology’,
‘Prostaglandin E2’, ‘PGE2’, ‘Antimicrobial peptides’,
‘Neutrophils’, ‘Macrophages’, ‘Dendritic cells (DC)’,
‘Postpartum sepsis’, and ‘Puerperal sepsis’. Additional
references were identified within bibliographies pro-
vided by PubMed-cited studies. The literature was
reviewed through August 31, 2011.
Postpartum sepsis
An Overview
Globally, puerperal infections cause morbidity in
5–10% of all pregnant women with over 75,000
deaths each year.6,7 Despite efforts to meet the Uni-
ted Nations Millennium Development Goal 5
(improve maternal health), the maternal mortality
ratio has not improved and infections are an impor-
tant reason.8 Several bacterial pathogens can cause
postpartum sepsis. While not the scope of this
review, Group B Streptococcus is more prevalent than
GAS, but typically causes less severe maternal dis-
ease.9 Other causal organisms include staphylococci,
Mycoplasma, Chlamydia, Clostridium sordellii, coliform
bacteria, and bacteria associated with polymicrobial
vaginosis.10 However, GAS postpartum infections
remain the most common cause of severe maternal
postpartum infections and death worldwide.11,12
Following efforts by Semmelweis and others to
popularize hand hygiene and raise the standards of
hospital cleanliness, maternal postpartum infections
decreased drastically (reviewed in Ref. 13). Despite
the dramatic and sustained decreases in postpartum
GAS infections and sepsis experienced in the 20th
century, the past two decades have witnessed an
unexplained increase in severe postpartum GAS
infections, resulting in greater numbers of maternal
deaths worldwide.3,8,14 This re-emergence has placed
a new urgency to better understand the host–micro-
bial determinants of disease that might be targeted
for improving preventive and therapeutic measures.
Group A Streptococcus is a ubiquitous human path-
ogen that causes a wide array of disease including
cellulitis, pharyngitis, necrotizing soft-tissue infec-
tions, scarlet fever, rheumatic fever, and invasive
puerperal infections. Puerperal infections present rap-
idly, within 2- to 48-hr postpartum and can be non-
specific, delaying treatment. Primary symptoms
include myalgias, fever, confusion, euphoria, dizzi-
ness, and abdominal pain.15 Once GAS is diagnosed,
the infection is often advanced. Notably, there does
not appear to be an increase in GAS antibiotic resis-
tance,16 so other factors must underlie the re-emer-
gence of GAS postpartum infections.
Routes of Maternal Infection
Group A Streptococcus can be found in the normal
biota of the FRT, but its colonization is considered to
be relatively rare (0.03%) and its presence alone is
not sufficient to cause disease.17 However, GAS is
asymptomatically carried on the skin or in the throat
by 5–30% of the population and is easily spread by
person-to-person contact or aerosolization.18 The
host and microbial factors that influence colonization
progressing to infection remain unresolved, but it is
apparent that postpartum and pregnant women are
predisposed to bacterial infections in general
(reviewed in Ref. 19).
Women can be a source of contamination of their
own reproductive tract. Some mothers with a recent
history of sore throat succumb to GAS postpartum
sepsis,9 suggesting that some women infect them-
selves after delivery, presumably through the con-
tamination of the perineum or through bacterial
travel in the bloodstream from distal organ sites.
Another frequent source of GAS exposure in the
maternal environment is through interaction with
children in the house or at work. In a recent report,
all investigated patients who died from GAS postpar-
tum sepsis had recent contact with children (fre-
quent GAS carriers) in their home or work
environment.9 Lamagni et al.20 demonstrated that
invasive GAS infections as a whole are on the rise in
the general population, perhaps contributing to the
increase in maternal exposure in the community.
Because of the presence of asymptomatic carriers,
nosocomial infections are a significant potential
route of maternal infection. The high incidence of
healthcare-associated GAS infections in the time of
Semmelweis was due to asymptomatic healthcare-
worker carriers, resulting in sporadic postpartum
GAS outbreaks in hospitals.6,21 Cesarean section has
been called ‘the single most important risk factor’ for
postpartum maternal infection in a hospital and this
may be due to several factors, but one obvious factor
is the invasive nature of the surgery.21,22 Antibiotic
administration during or after surgery significantly
reduces the risk for postpartum infection22 but is not
100% effective at preventing infections from pro-
gressing and rapidly causing maternal death.9 It is
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easy to regard uncomplicated pregnancies with vagi-
nal deliveries as low-risk for sepsis in a hospital set-
ting, but there has been an increase in postpartum
sepsis following these seemingly unremarkable deliv-
eries.9 The non-specific symptoms at the onset of
GAS sepsis result in healthy women becoming criti-
cally ill and dying within a few hours or days.9,23
Regardless of delivery type, postpartum patients
have a 20-fold increased incidence of GAS-induced
disease compared to non-pregnant women.24 Inter-
estingly, this increased incidence is higher than that
observed in adults over the age of 65 years, and the
typical age group associated with increased incidence
of GAS infections.25 The high incidence of asymp-
tomatic carriage and multiple routes of inoculation
(Fig. 1) result in a significant risk for GAS postpar-
tum infections.
Microbiology and immunology of GAS sepsis
GAS Virulence Factors and STSS
Group A Streptococcus is a versatile human pathogen
that utilizes numerous virulence factors to evade
immune recognition or clearance. Several recent
reviews describe in detail the microbial factors that
contribute to GAS pathogenesis26–30 and will not be
discussed in detail. GAS virulence factors aid in
evading phagocytosis and facilitate in adherence to
host cells, leading to colonization and invasion of
the host.26,31–35 In addition, GAS has a family of
bacterial antigens that are associated with STSS.36,37
This family includes Streptococcal pyogenic exotoxin
A (SpeA), SpeC, and others that bind to the MHC
class II molecules and T-cell receptors, resulting in
an excessive release of immunomodulators that acti-
vate complement, coagulation, and fibrinolytic cas-
cades, resulting in toxic shock and death. STSS has
been reported with invasive GAS soft-tissue infec-
tions with a mortality rate of approximately 30%.3
A recent study of 11 European countries showed a
13% incidence level for STSS from GAS infections
with a mortality rate of up to 50%.38 SpeA is the
superantigen most commonly associated with GAS
infections that result in STSS in the United
States,27,39 and genome sequence comparisons of
GAS patient isolates reveal new variants of speA,
which may be contributing to the increased severity
of these clinical strains in postpartum infections.40,41
Immune Recognition of GAS
Despite diverse evasion strategies, GAS is recognized
by the innate immune response. GAS is recognized
by an unidentified MyD88-dependent receptor,
which is independent of TLR2, TLR4, and TLR9 acti-
vation,42 and in vitro studies demonstrate GAS acti-
vation of p38 MAPK, NF-jB, TNFa, IL-6, and type 1
IFN production,42 indicating host immune activation.
GAS was long considered an extracellular pathogen,
but recent research has demonstrated GAS survival
within multiple host cell types, including epithelial
cells, neutrophils, and macrophages.43–48 Biopsies
from patients with severe GAS tissue infections con-
tained viable GAS within macrophages, confirming
their intracellular survival ability.44 GAS survival in
epithelial cells may contribute to severe GAS post-
partum infections by providing a location for sys-
temic invasion or the initiation of STSS. The next
few sections detail the potential roles for the diverse
cellular components of innate immunity in defense
against reproductive tract GAS infection.
Epithelial cells and antimicrobial peptides
Epithelial cells (EC) play a pivotal role in maintain-
ing maternal health by forming tight junctions that
provide a physical barrier against potentially
Fig. 1 Potential routes of Group A Streptococcus (GAS) infection dur-
ing pregnancy and postpartum. GAS can enter the incision made dur-
ing cesarean section, leading to a quickly disseminating infection. GAS
infections can also result from distal infections (i.e., pharyngitis) where
the bacterium travels through the bloodstream, infecting the repro-
ductive tract and developing fetus. The vagina is another source of
GAS infections when maternal colonization is present or when the per-
ineum is contaminated after environmental exposures to GAS.
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pathogenic microbes, through antimicrobial mole-
cule release, and TLRs 1–9 expression.49,50 Studies of
chemokine and cytokine production by EC during
pregnancy indicate an overall immune hypo-respon-
siveness with reduced levels of IL-1b, IL-8, and IL-6
in cervical fluid.51 The altered antimicrobial peptide
production of epithelial cells in the FRT may play a
role in the ability of clinical strains of GAS to cause
more severe postpartum infections. Numerous
endogenous antimicrobials actively protect the preg-
nant uterus including a- and b-defensins, found in
healthy pregnant females (reviewed in Refs. 52,53).
SLPI and elafin are two other antimicrobials present
in the pregnant uterus54 that have anti-protease and
anti-inflammatory activities and are thought to regu-
late inflammation during pregnancy and labor.52
However, certain pathogens, including GAS, can
degrade these antimicrobials.55,56 GAS might inhibit
the innate immune response through molecules like
SpeB that can cleave host molecules like LL-37, an
antimicrobial peptide.20,27 LL-37 is found throughout
the FRT and plays an important role in preventing
infections, but LL-37 can be inhibited by PGE2,
which is up-regulated at the end of pregnancy,
which may contribute to susceptibility to GAS infec-
tions in the FRT.52,57
Macrophages
Macrophages are an important first line of defense
against invading pathogens through phagocytosis,
antigen presentation, and cytokine production.58–61
Previous mouse studies demonstrate that when mac-
rophage populations are depleted during a sublethal
systemic GAS infection, mice are significantly more
susceptible.62 Macrophages can also promote chemo-
taxis responses to GAS infections through the activa-
tion of transcription factors involved in cytokine
signaling and chemokine expression.63,64 However,
macrophages in the FRT have altered activity com-
pared to macrophages found in other organ ⁄ tissue
sites (reviewed in Ref. 65).
Macrophages account for approximately 10% of
the total leukocytes in the FRT66 and display pheno-
typic changes and up-regulated intracellular reactive
oxygen species during pregnancy.67–70 Estrogen and
progesterone levels alter the migration of macro-
phages in the FRT, and there is cyclic variation in
macrophage movement because of the hormonal
regulation of cytokine and chemokine expres-
sion.71,72 The mechanism behind these cellular alter-
ations remains unknown and controversial in the
field and further work must be performed to eluci-
date the role of hormone alterations, prostaglandins,
stage of pregnancy, the indigenous microbiota of the
reproductive tract, and other factors that may alter
macrophage response to GAS infections in pregnant
and postpartum women.
Dendritic cells
Dendritic cells (DC) are present throughout the FRT
and within the epithelial layer73,74 and are the most
potent antigen-presenting cells.75 DC play a vital role
in maintaining Th1 ⁄Th2 balance76–78 and secrete sol-
uble immune modulators that alter DC cytokine pro-
duction.79 The ability of estradiol and progesterone
to alter DC differentiation remains controversial, but
GAS can inhibit DC maturation80 and may be a
potential mechanism of GAS colonization and dis-
ease in the FRT.
Neutrophils
Neutrophils are an essential part of the innate
immune response to invading bacterial pathogens.
Neutrophils efficiently, phagocytose bacteria, activate
the production of reactive oxygen species and neu-
trophil degranulation and result in bacterial killing
(reviewed in Ref. 81). GAS utilizes several virulence
factors to evade ingestion and cellular recruitment
by neutrophils in soft-tissue infections.26,82,83 Upon
neutrophil phagocytosis, GAS up-regulates genes
involved in tempering oxidative stress, in cell enve-
lope components, and virulence factors,81,84,85 sug-
gesting that GAS can effectively respond to different
host environments to promote persistence. The rapid
response to bacterial infections in soft tissue makes it
likely that neutrophils will play a role in susceptibil-
ity to GAS postpartum sepsis.
GAS and Host Genetic Susceptibility
Emerging data suggest that host genetics play a sig-
nificant role in the outcome of GAS infections.86,87
Hypervirulent strains of GAS emerged globally in the
1980s and have persisted since, but despite the
increase in virulence, there is a wide spectrum of
clinical manifestations associated with these strains
of GAS,88,89 suggesting that host genetics are a fac-
tor.90–93 The severity of the response to GAS varies
by patient,93–95 and the level of host cytokine pro-
duction is correlated with the severity of dis-
ease.93,96–100 Of patients with previous postpartum
infections, there were significant changes in allele
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frequencies compared to control patients for TLR9,
hsp70, and IL-1b, suggesting that innate immune
response gene polymorphisms are associated with
susceptibility to severe GAS puerperal sepsis.101
These studies have helped to clarify some of the host
immune factors that influence infection risk, but fur-
ther research is needed to clarify genetic predisposi-
tions of pregnant and postpartum women to GAS
infection (or its complications).
Postpartum Physiology and Immunology
The gravid FRT environment is unique in its
immunology (reviewed in Ref. 19). The maternal
immune system must be tolerant to the indigenous
bacteria in the reproductive tract, to paternal anti-
gens in sperm, and to the immunologically distinct
fetus. Despite this immunological tolerance, the FRT
must be able to detect and respond to potentially
pathogenic organisms. Pregnancy takes place in a
physiologically and immunologically distinct organ
with its own mucosal barrier (uterus and decidua)
and accommodates an allogeneic fetus.102 In addi-
tion, hormonal products in the FRT alter the
immune response, and the fetus progressively chal-
lenges the maternal immune system as its size and
complexity increases. Prostaglandin (PG)E2, IL-4,
and IL-10 are induced by pregnancy and suppress
the maternal Th1 immune response (reviewed in
Ref. 103), and the systemic down-regulation of the
Th1 response results in immune alterations that
promote maternal susceptibility to infection.70 Preg-
nancy has often been referred to as a Th2-type
immune state, but pregnancy is a modulated
immune state that is not simply anti-inflammatory,
but is continually changing during fetal develop-
ment.104–106 Although much is known about immuno-
modulatory aspects of gestation, these findings have
not been studied in the context of invasive GAS
infections.
Prostaglandin E2
The lipid mediator PGE2 deserves special mention
because it has emerged as an important modulator
of host immunity, especially during pregnancy and
the postpartum period.107–112 PGE2 is an arachidonic
acid–derived mediator that modulates cell behavior
via the ligation of four distinct G protein–coupled
receptors called E prostanoid (EP) receptors, which
are numbered EP1-4 (reviewed in Ref. 113).
Throughout gestation, PGE2 dampens maternal
immune responses against fetal tissues107–110,114 and
regulates cervical softening and uterine contractions
during labor, where it is found at increased lev-
els.111,112,115 It is also a critical negative regulator of
the host immune response, with the ability to down-
regulate lymphocyte and neutrophil activity,116 to
inhibit production of Th1 cytokines (IL-12 and
IFNc), and to enhance production of Th2 cytokines
(IL-5 and IL-10).117–119 Elevation in PGE2 levels has
previously been shown to play a role in host suscep-
tibility to infections in many patient populations
including pregnant women.114,120–129
The capacity for PGE2 to regulate host–microbial
interactions is increasingly evident in the context of
streptococcal infections.130–136 In 1982, Short
et al.137 demonstrated increased survival in animals
when PGE2 synthesis was inhibited during Group B
Streptococcus sepsis. Prostaglandin endoperoxide syn-
thase 2 (COX-2) is the enzyme that converts arachi-
donic acid into prostaglandin endoperoxide H2
(PGH2) before PGH2 is converted into other prosta-
glandins. In 2010, Goldman et al. demonstrated that
COX-2 is up-regulated in human and mouse tissues
infected by GAS.130,138 Using a mouse model of GAS
bacteremia and in vitro studies of bone marrow–
derived macrophages, they established that PGE2 sig-
naling via EP2 receptors and cAMP elevation sup-
pressed host defenses against GAS.130 An unbiased
systems genetics approach later identified two PGE2
synthase enzymes (mPGES-1 and -2) as key
participants mediating susceptibility to GAS.86 How-
ever, little is known about PGE2 and GAS in the
FRT.139–141
FRT Mucus, pH, and the Indigenous Microbiota
Vaginal colonization by GAS appears to be an impor-
tant preceding event in some cases of puerperal sepsis
(following vaginal delivery), yet host–microbial inter-
actions that determine the capacity for GAS to colo-
nize and invade the mucosal surfaces of the FRT need
further study. In addition, the innate immune mecha-
nisms that prevent GAS from ascending through the
cervical canal into the postpartum uterus remain
incompletely understood. Mucus within the FRT pro-
tects epithelial cells from bacterial infections through
several mechanisms. Mucus can physically trap
potential pathogens and inhibit pathogen survival
because of the low pH, immunoglobulins, and anti-
microbial peptides.142,143 The changes in mucus in
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the postpartum FRT and its effect on GAS coloniza-
tion and dissemination remain unknown.
The indigenous bacteria in the reproductive tract
also provide pathogen resistance through several
means, including competitive exclusion of patho-
genic microbes and contributing to the acidic vaginal
environment through lactic acid production. Lacto-
bacillus spp. are the most common bacteria present
across all ethnic groups and produce lactic acid in
the FRT.142,144 Few studies have been performed to
investigate individual variation between women
over time, but these preliminary studies suggest that
the bacterial diversity is dynamic even among indi-
viduals and the vagina is implicated as a significant
source of infectious organisms resulting in preterm
labor.142,145–149 Membranes collected from healthy
women following at term cesarean sections demon-
strate bacterial DNA in up to 70% of samples, indi-
cating a dynamic host control of individual bacterial
diversity in healthy pregnancies.150 The role of the
indigenous microbiota in the reproductive tract and
its interactions with the host immune response dur-
ing GAS postpartum infections remain unknown,
and whether probiotic approaches would be success-
ful at preventing puerperal GAS infections depends
upon more research into how the microbiota creates
a colonization and infection resistance against this
pathogen.
Conclusions
Pregnancy is a highly immunomodulated state
that permits implantation and development of the
immunologically distinct fetus. This may result in an
immunologically vulnerable FRT that is more easily
infected after delivery. The immune changes that
progress during pregnancy are complex and remain
largely uncharacterized, but recent research suggests
GAS infections are re-emerging and postpartum
patients are particularly prone to severe GAS infec-
tions that result in death.1–4 The mechanisms behind
GAS bacterial virulence, postpartum susceptibility,
and the immune response to FRT infections remain
poorly understood, and future work must be per-
formed to address the increase in maternal mortality
from postpartum GAS infections.
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